uniQure to Announce Third Quarter Financial Results
uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company, is gearing up to share important updates regarding its financial performance for the third quarter of 2025. Scheduled to be reported before the stock market opens, this event will take place in the coming days, promising to shed light on the company’s financial health and strategic direction.
Upcoming Conference Call Details
On the morning of the announcement, management will hold a conference call to discuss the financial results in detail. The call is set for 8:30 a.m. ET, allowing investors and analysts an opportunity to engage directly with the company’s leadership. Those interested in participating can join the call by dialing the designated numbers provided in the announcement.
Engaging with the Financial Community
The event will not only cover financial results but also provide insights into the company's ongoing initiatives and future roadmaps. To accommodate all interested parties, the conference will be accessible via a live webcast. This feature allows those who cannot join the call to still participate in the conversation. Post-event, a recording will be made available for 90 days, ensuring that stakeholders have ample opportunity to catch up on any missed information.
uniQure's Commitment to Gene Therapy
As a leader in the gene therapy sector, uniQure is dedicated to developing potential breakthroughs for patients dealing with severe medical conditions. Their recent successes, particularly in gene therapy for hemophilia B, represent a significant milestone in the genomic medicine landscape. This pioneering treatment offers hope by providing patients with potentially lifelong solutions through a single administration.
Advancements in Gene Therapy Pipeline
uniQure is actively expanding its portfolio with innovative therapies targeting various severe diseases. Their pipeline includes treatments aimed at conditions such as Huntington's disease, refractory temporal lobe epilepsy, and ALS. The strategic direction underlines their commitment to addressing pressing medical needs while pushing the boundaries of what gene therapy can achieve. As they continue to advance their research efforts, the upcoming financial results are expected to highlight progress and future ambitions.
Uniqure's Investor Relations
Investor relations are critical for uniQure as they advance their mission. The company fosters transparency and communication, making sure investors are well-informed about developments and project timelines. They emphasize building trust and reliability within the financial community. Key contacts for investors include Chiara Russo, who is available for inquiries related to financial performance, and Tom Malone for media relations. Both are accessible via direct phone numbers and email for any additional questions or media needs.
Frequently Asked Questions
When will uniQure announce its third quarter financial results?
uniQure is set to announce its Q3 financial results before the market opens on Monday, November 10, 2025.
How can I participate in the conference call?
To join the conference call, dial (646) 307-1963 or toll-free (800) 715-9871, and enter the passcode 2196195 about 15 minutes before it starts.
What is the focus of uniQure’s upcoming financial report?
The report will detail uniQure’s financial performance, ongoing projects, and strategic plans, particularly regarding its gene therapy initiatives.
Is the conference call accessible to the public?
Yes, the conference call will be available via a live webcast, allowing the public to access the discussion and insights provided by the management team.
Who should I contact for more information about uniQure’s financial results?
You can reach out to Chiara Russo for investor-related inquiries or Tom Malone for media questions. Both are available via their listed direct contact numbers and emails.
